{"id":"amivantamab-iv","safety":{"commonSideEffects":[{"rate":"null","effect":"Interstitial lung disease"},{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Amivantamab is a fully human monoclonal antibody that targets the extracellular domain of EGFR mutations, including exon 20 insertions.","oneSentence":"Targeting EGFR","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:56.651Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07042295","phase":"PHASE2","title":"Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-23","conditions":"Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma","enrollment":86},{"nctId":"NCT06667076","phase":"PHASE2","title":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":480},{"nctId":"NCT05801029","phase":"PHASE2","title":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-18","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":60},{"nctId":"NCT04538664","phase":"PHASE3","title":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-10-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":308},{"nctId":"NCT05379595","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":"Advanced or Metastatic Colorectal Cancer","enrollment":225},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT05663866","phase":"PHASE2","title":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":68},{"nctId":"NCT05388669","phase":"PHASE3","title":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-05","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":418},{"nctId":"NCT05908734","phase":"PHASE1, PHASE2","title":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":71},{"nctId":"NCT06385080","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-22","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":287},{"nctId":"NCT05488314","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":57},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT06083857","phase":"PHASE1, PHASE2","title":"PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-18","conditions":"Non-small Cell Lung Cancer","enrollment":3},{"nctId":"NCT05117931","phase":"PHASE2","title":"A Study of Amivantamab in People With Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-02","conditions":"Esophagogastric Cancer","enrollment":25},{"nctId":"NCT06532032","phase":"PHASE1, PHASE2","title":"A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-23","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":12},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT07392658","phase":"PHASE2","title":"Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2025-12-02","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer","enrollment":33},{"nctId":"NCT04988295","phase":"PHASE3","title":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-17","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":776},{"nctId":"NCT04487080","phase":"PHASE3","title":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-30","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1074},{"nctId":"NCT02609776","phase":"PHASE1","title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-24","conditions":"Non-Small-Cell Lung Cancer","enrollment":751},{"nctId":"NCT04965090","phase":"PHASE2","title":"A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-09-30","conditions":"Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer","enrollment":43},{"nctId":"NCT06116682","phase":"PHASE2","title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-11-19","conditions":"Lung Non-Small Cell Carcinoma","enrollment":88},{"nctId":"NCT05299125","phase":"PHASE2","title":"Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2023-05-24","conditions":"Metastatic Non-small Cell Lung Cancers","enrollment":54},{"nctId":"NCT06632236","phase":"PHASE1","title":"5G-EMERALD: Amivantamab in Malignant Brain Tumours","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2024-10-09","conditions":"Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant","enrollment":12},{"nctId":"NCT06855849","phase":"PHASE2","title":"An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-05","conditions":"RAS/BRAF Wild-type Advanced Colorectal Cancer Patients","enrollment":85},{"nctId":"NCT05241873","phase":"PHASE1","title":"(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations","status":"TERMINATED","sponsor":"Blueprint Medicines Corporation","startDate":"2022-03-04","conditions":"Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms","enrollment":103},{"nctId":"NCT04945733","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-08-30","conditions":"Stomach Neoplasms, Esophageal Neoplasms","enrollment":62},{"nctId":"NCT04085315","phase":"PHASE1","title":"Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer","status":"RECRUITING","sponsor":"Collin Blakely","startDate":"2019-11-12","conditions":"Lung Cancer Metastatic, EGFR Gene Mutation","enrollment":38},{"nctId":"NCT03767075","phase":"PHASE2","title":"A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)","status":"RECRUITING","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2018-12-10","conditions":"Advanced Solid Tumor","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-61186372","RYBREVANT"],"phase":"phase_2","status":"active","brandName":"Amivantamab IV","genericName":"Amivantamab IV","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amivantamab IV is an epidermal growth factor receptor (EGFR) inhibitor, classified as an antibody-based inhibitor. It is being studied in clinical trials for various conditions, including metastatic non-small cell lung cancer, squamous cell carcinoma of the head and neck, and advanced solid tumors.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-05-21T00:00:00.000Z","mah":"JANSSEN BIOTECH","brand_name_local":"RYBREVANT","application_number":"BLA761210"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2021-12-09T00:00:00.000Z","mah":"Janssen-Cilag International N.V.","brand_name_local":"Rybrevant","application_number":"EMEA/H/C/005454"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}